These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15772819)

  • 1. Monitoring treatment response by the hepatitis C virus core antigen assay.
    Lindh M; Lagging M; Westin J; Wejstål R; Norkrans G
    Eur J Clin Microbiol Infect Dis; 2005 Mar; 24(3):230-2. PubMed ID: 15772819
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
    Pivert A; Payan C; Morand P; Fafi-Kremer S; Deshayes J; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F
    J Clin Microbiol; 2006 Feb; 44(2):417-22. PubMed ID: 16455894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
    Veillon P; Payan C; Picchio G; Maniez-Montreuil M; Guntz P; Lunel F
    J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
    Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
    J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
    Sasase N; Kim SR; Kim KI; Taniguchi M; Imoto S; Mita K; Hotta H; Shouji I; El-Shamy A; Kawada N; Kudo M; Hayashi Y
    Intervirology; 2008; 51 Suppl 1():70-5. PubMed ID: 18544951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.
    Fujino T; Nakamuta M; Aoyagi Y; Fukuizumi K; Takemoto R; Yoshimoto T; Miyahara T; Harada N; Sakai H; Nakashima M; Enjoji M
    J Dig Dis; 2009 Feb; 10(1):21-5. PubMed ID: 19236543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.
    Vermehren J; Susser S; Berger A; Perner D; Peiffer KH; Allwinn R; Zeuzem S; Sarrazin C
    J Clin Virol; 2012 Sep; 55(1):17-22. PubMed ID: 22698697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients.
    Yoneda S; Umemura T; Katsuyama Y; Kamijo A; Joshita S; Komatsu M; Ichijo T; Matsumoto A; Yoshizawa K; Ota M; Tanaka E;
    J Infect Dis; 2011 Apr; 203(8):1087-95. PubMed ID: 21398397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin.
    Buti M; Mendez C; Schaper M; Sauleda S; Valdes A; Rodriguez-Frias F; Jardi R; Esteban R
    J Hepatol; 2004 Mar; 40(3):527-32. PubMed ID: 15123370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.
    Tedder RS; Tuke P; Wallis N; Wright M; Nicholson L; Grant PR
    J Viral Hepat; 2013 Jan; 20(1):65-71. PubMed ID: 23231086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADVANCE study begins enrollment.
    AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
    [No Abstract]   [Full Text] [Related]  

  • 12. The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment.
    Pradat P; Maynard M; Buti M; Berthillon P; Picchio G; Tillmann HL; Wiegand J; Voirin N; Manns MP; Esteban JI; Martinot M; Marcellin P; Trepo C
    J Med Virol; 2004 Jul; 73(3):392-6. PubMed ID: 15170634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*.
    González V; Padilla E; Diago M; Giménez MD; Solà R; Matas L; Montoliu S; Morillas RM; Pérez C; Planas R
    J Viral Hepat; 2005 Sep; 12(5):481-7. PubMed ID: 16108762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Christensen P; Leutscher P; Norkrans G;
    Hepatology; 2008 Aug; 48(2):695. PubMed ID: 18666232
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment for chronic hepatitis C, more opportunity, more challenge].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):481-3. PubMed ID: 19912676
    [No Abstract]   [Full Text] [Related]  

  • 17. [Difficult-to-treat patient with chronic hepatitis C: a challenge in clinical practice].
    Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):486-7. PubMed ID: 19912678
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C.
    Kim MN; Kim HS; Kim JK; Kim BK; Kim SU; Park JY; Kim do Y; Ahn SH; Han KH
    J Korean Med Sci; 2016 Sep; 31(9):1431-7. PubMed ID: 27510387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The study of optimal treatment in patients with refractory chronic hepatitis C].
    Chen XY; Zhang YH
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):488-9. PubMed ID: 19912679
    [No Abstract]   [Full Text] [Related]  

  • 20. Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C.
    Figlerowicz M; Sluzewski W; Kowala-Piaskowska A; Mozer-Lisewska I
    Eur J Pediatr; 2004 Apr; 163(4-5):265-7. PubMed ID: 14991399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.